Historical Stock Chart
1 Month : From Oct 2018 to Nov 2018
By Stephen Nakrosis
Merck & Co. Inc (MRK) said Friday the U.S. Food and Drug Administration approved the use of Keytruda in some patients suffering with hepatocellular carcinoma.
Hepatocellular carcinoma is a disease of the liver, usually seen in patients with chronic liver disease and cirrhosis.
"The approval of Keytruda for advanced hepatocellular carcinoma marks the second FDA approval for hepatocellular carcinoma in Merck's oncology portfolio this year," said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.
The company said continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The latest approval marks the 14th indication for Keytruda.
Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires
November 09, 2018 16:58 ET (21:58 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.